Cheng and colleagues identified that miRNA-137 reduces the expression of the glycoprotein follistatin-like 1 (FSTL1), a glycoprotein that was overexpressed compared to samples from other BC subtypes and control samples [123]. This evidence concerns the gene FSTL1 and breast cancer.